Search

everythinglearnresearchcommunity

for

Search:↓

The study suggested certain immune cells might cause alopecia areata, but it was retracted.

JAK inhibitors are effective for treating moderate-to-severe alopecia areata.

Inhibiting IL-17 and IL-23 improves wound healing in obese, diabetic mice by promoting healing macrophages.

The document concludes that systemic autoimmune diseases are complex, incurable, and require ongoing treatment and research.

Combined therapy reduces inflammation and restores immune balance in alopecia areata patients.

Interferons are effective for some skin conditions and cancers, but can have side effects and need more research for optimal use.

Breast implants are linked to autoimmune symptoms, with over half of patients feeling better after removal, but the exact cause is unclear and may involve bacterial biofilm.

Psoriasis patients on biologic therapy have a weaker immune response to COVID-19 vaccination than healthy people.

The review suggests that other immune cells besides CD8+ T cells may contribute to alopecia areata and that targeting regulatory cell defects could improve treatment.

The model showed that immune system guardians and the cytokine interferon-γ are key in alopecia areata progression.

Local inflammation worsens autoimmune skin conditions by increasing antibody buildup.

Targeted immune modulation can help achieve stable remission in alopecia areata.

Researchers found that certain miRNAs, which affect immune system regulation, are differently expressed in mice with a hair loss condition compared to healthy mice.

Sequential immunotherapy can effectively treat alopecia areata by managing inflammation and promoting hair regrowth.

New findings suggest targeting IL-23 could treat psoriasis, skin cells can adapt to new roles, direct conversion of skin cells to blood cells may aid cell therapy, removing certain tumor cells could boost cancer immunotherapy, and melanoma may have many tumorigenic cells, not just cancer stem cells.

Immune cells and cytokines significantly affect pathological scar development.

Certain microRNAs may help treat alopecia areata by targeting immune pathways.

Controlled microflora in animals delays immune cell maturation and affects immunity.

A new mutation in the STING protein causes a disease with lupus-like symptoms and responds well to a specific inhibitor treatment.

The meeting highlighted major advances in skin research, including new findings on skin microbes, genetic links to skin diseases, and improved treatments for various conditions.

Psoriasis involves an imbalance between certain immune cells, and targeting these could help restore skin health.

Alopecia areata involves complex immune and genetic factors, with potential treatment targets identified, but more research is needed.

NK cells play a role in skin diseases like eczema and psoriasis.

Patients with skin immune diseases need better education on UV protection to improve compliance.

Vitiligo is caused by the immune system attacking skin pigment cells.

Controlling immune responses with biomaterials can reduce scarring and improve skin regeneration.

Cancer patients treated with immune checkpoint inhibitors may develop alopecia, but some hair regrowth is possible with treatment.

Janus kinase inhibitors are promising drugs for treating autoimmune and inflammatory diseases.

Immuno-cosmeceuticals from chicken egg yolk can effectively repair and improve damaged hair.

ILC1-like cells can cause alopecia areata by attacking hair follicles.